ISDS Case Map
intellectual property
Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada–European Union trade agreement
Doctors Without Borders/Medecins Sans Frontieres (MSF) and other health groups have reiterated concerns about harmful intellectual property provisions in the RCEP
As published by the European Commission
Threats to affordable access to medicines continue unabated
As trade negotiators from 16 countries gather in Indonesia to deliberate the terms of trade agreement — the Regional Comprehensive Economic Partnership agreement (RCEP), access to low-cost generic medicines is under grave threat.
The problem with free trade deals is they rarely are about trade. In fact, trade usually is a side issue. And the TPP was a classic case in point.
CETA drug-patent extension applies only to new products, and higher costs are likely at least 8 years away
Trump tells a half truth about why the TPP is a bad deal
The launch of the Asean Economic Community (AEC) in December 2015 was a milestone for Asean economic integration, which is, however, an ongoing process.
Experts have been warning for years that Canada’s trade deal with the European Union would add billions to the cost of pharmaceuticals in Canada, but the government itself apparently did not study the issue.
